# Study of HEMAX PFS Versus EPREX/ ERYPO® in Predialysis Chronic Kidney Disease

> **NCT04036253** · PHASE3 · COMPLETED · sponsor: **Bio Sidus SA** · enrollment: 43 (actual)

## Conditions studied

- Anemia of Chronic Kidney Disease

## Interventions

- **BIOLOGICAL:** Erythropoietin alfa

## Key facts

- **NCT ID:** NCT04036253
- **Lead sponsor:** Bio Sidus SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-28
- **Primary completion:** 2021-06-15
- **Final completion:** 2021-08-31
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2025-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04036253

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04036253, "Study of HEMAX PFS Versus EPREX/ ERYPO® in Predialysis Chronic Kidney Disease". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT04036253. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*